Brief: Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint
17/12/2025 11:45
Dec 17 (Reuters) - PFIZER: PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL & STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, & OVERALL SURVIVAL PFIZER: PATHOLOGIC COMPLETE RESPONSE RATE FOR NEOADJUVANT PADCEV PLUS PEMBROLIZUMAB VERSUS NEOADJUVANT CHEMOTHERAPY WAS MET PFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITY PFIZER: SAFETY PROFILE FOR PADCEV PLUS PEMBROLIZUMAB WAS CONSISTENT WITH KNOWN PROFILE OF TREATMENT REGIMEN Further company coverage: 4503.T (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn